The latest update is out from Revance Therapeutics (RVNC).
Revance Therapeutics Inc. has reported a significant increase in its aesthetic portfolio, now boasting over 8,000 individual accounts. Impressively, more than 4,200 of these accounts have placed orders for DAXXIFY®, marking a substantial uptick from previous figures released during the second quarter of 2024. This growth highlights the company’s expanding reach in the aesthetics market.
Find detailed analytics on RVNC stock on TipRanks’ Stock Analysis page.
